3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

Home-Grown Partnership Pays Dividends

 
• By Brian Yang
  
winners from China NRDL scheme
FIRST SUBCUTANEOUS IMMUNO-ONCOLOGY DRUG APPROVAL FROM CHINA'S 3D MED AND ALPHAMAB • Source: Alamy

More from New Products

More from Scrip